What Limits Direct Compression of Aceclofenac to Tablet Hardness Below 35 N?

Direct compression of aceclofenac as a single-component blend is limited by its needle-like crystal habit and low bulk density, which commonly falls below 0.32 g/mL for unmilled material. The powder blend exhibits Carr's index values above 30% and angle of repose exceeding 40°, creating die fill variation greater than ±5% on high-speed rotary presses. For a 100 mg dose with target tablet weight 250–300 mg, a high-shear wet granulation route is therefore used on production-scale mixers such as GEA Aeromatic-Fielder or Collette units with bowl volumes from 65 L to 600 L. Aceclofenac is pre-blended with lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium at 2.0–5.0% w/w before binder addition. Povidone K30 dissolved in purified water at 5.0–10.0% w/w is sprayed onto the agitated mass while impeller speed is maintained at 150–250 rpm and chopper speed at 1500–3000 rpm. Wet massing time is held between 3–8 min because prolonged kneading generates excess fines after drying and reduces granule porosity. The wet mass is dried in a fluid-bed dryer at inlet air temperature 60–70°C until loss on drying is 1.0–2.5% w/w. Temperatures above 75°C are avoided because the ester linkage of aceclofenac undergoes hydrolytic cleavage to diclofenac under accelerated thermal stress. Dried granules are milled through a 1.0 mm screen using a Quadro Comil 197 or equivalent conical mill. Colloidal silicon dioxide at 0.5–1.0% w/w and magnesium stearate at 0.5–1.0% w/w are added in final blending; lubrication time is capped at 5 min to avoid overblending that reduces tablet tensile strength. Compression is performed on a rotary tablet press at 10–18 kN force, producing tablets with hardness 50–100 N, friability below 1.0% per Ph. Eur. 2.9.7, and disintegration below 15 min per Ph. Eur. 2.9.1. Dissolution acceptance follows USP <711> using 900 mL of pH 6.8 phosphate buffer at 50 rpm paddle speed, with typical release above 80% at 30 min. Batch-to-batch variance in granule density is the predominant production bottleneck; a change in binder solution viscosity exceeding ±10% alters median granule size by 150–200 µm and shifts tablet friability by up to 0.4%.

On automatic capsule filling lines, powder bed uniformity and the shape factor of milled aceclofenac dominate fill weight consistency. Unmilled aceclofenac crystals often show an acicular habit with aspect ratios above 3:1, producing agglomeration and variable flow through the dosing disk. Pre-milling through a 0.5 mm sieve or air-jet milling to D90 below 100 µm is therefore applied before blending. A direct-fill powder blend for 100 mg capsules commonly includes microcrystalline cellulose, lactose monohydrate, pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The blend is loaded into an intermittent-motion capsule filler, where tamping pin force and pin number are adjusted to maintain fill weight 200–250 mg for size 2 or size 3 capsules. Mass uniformity is evaluated per Ph. Eur. 2.9.5 and content uniformity per Ph. Eur. 2.9.6 or USP <905>. Flow performance is tested using Ph. Eur. 2.9.36 powder flow or USP <1174>; the target Carr's index is below 25% and the angle of repose below 35°. Environmental humidity must be kept below 40% RH because the ester moiety of aceclofenac is susceptible to moisture-induced hydrolysis. Excipients with moisture content above 1.5% w/w are pre-dried at 50°C for 2–4 h before blending. Hard gelatin or hypromellose shell selection follows incoming inspection for moisture and cross-linking; gelatin shells stored above 60% RH exhibit dissolution delay in pH 6.8 buffer and are rejected. Dissolution testing follows USP <711> with 900 mL of pH 6.8 phosphate buffer at 50 rpm paddle speed; release from capsules is typically below tablet release in the first 15 min due to shell rupture time. The most frequent production failure on capsule lines is weight drift after 60–90 min of continuous operation, caused by magnesium stearate redistribution within the powder bed; lubricant levels above 1.0% w/w and fill speeds above 60,000 capsules/h intensify this drift.

When Roller Compaction Replaces Wet Granulation in Humidity-Sensitive Supply Chains

Roller compaction is selected when ambient humidity in the production zone frequently exceeds 60% RH or when the API batch has a known hydrolytic degradation rate above 0.2% per month at 40°C/75% RH. The process avoids aqueous binder addition and reduces the time that aceclofenac is exposed to elevated moisture. Dry granulation is run on roller compactors such as the Alexanderwerk WP120 or Gerteis Mini-Pactor with roll pressure 8–15 kN/cm, roll speed 2–5 rpm, and roll gap 2–4 mm. Ribbon density is a critical intermediate variable; ribbons with density below 1.1 g/cm³ produce weak granules and high fines, while ribbons above 1.4 g/cm³ reduce tablet porosity and slow disintegration. Ribbons are milled through a 1.0 mm or 1.25 mm screen, with fines below 250 µm recycled to the feed hopper at a controlled ratio not exceeding 20% to maintain flow. The resulting granules are blended with extra-granular croscarmellose sodium at 2.0–4.0% w/w and magnesium stearate at 0.5–1.0% w/w. Tablets compressed from roller-compacted granules typically show hardness 40–80 N, lower than wet-granulated tablets at the same compression force, but friability remains below 1.0%. Dissolution in pH 6.8 buffer may be 10–15% lower at 15 min compared with wet granulation because of reduced internal granule porosity. This can be corrected by adding a superdisintegrant inside the ribbon or reducing roll pressure by 2 kN/cm. Process controls include ribbon density measurement by helium pycnometry or envelope density analysis, granule particle-size distribution by sieve analysis per Ph. Eur. 2.9.12, and loss on drying below 1.0% w/w. Published data for the long-term hydrolytic degradation of aceclofenac in roller-compacted granules stored at Zone IVb conditions is limited; accelerated stability at 40°C/75% RH for 6 months is required before release to tropical markets.

Under tropical climatic conditions (Zone IVb, 30°C/75% RH), oral granules packed in unit-dose sachets must remain free-flowing after 24 months without lumping or moisture gain above 2.0% w/w. Aceclofenac granules for oral suspension are prepared by wet granulation or dry blending followed by sieving to 0.5–1.0 mm. Because the API has an objectionable bitter taste, taste-masking is achieved with a polymer coating such as ethylcellulose or Eudragit E100 at 5–10% w/w weight gain. The coated API granules are blended with suspending agents such as xanthan gum at 0.3–0.8% w/w, sodium carboxymethylcellulose at 0.5–1.0% w/w, sorbitol or sucrose as a diluent, and a low-moisture flavor system. Silicon dioxide at 0.5–1.0% w/w is included to reduce electrostatic build-up during sachet filling on vertical form-fill-seal machines. The final granule blend is packed into Alu-Alu laminate sachets with a moisture vapor transmission rate below 0.1 g/m²/day. Fill weight for a 100 mg dose is typically 2–5 g depending on the diluent load. Dissolution testing for granules follows Ph. Eur. 2.9.3 using 900 mL of pH 6.8 phosphate buffer with paddle speed 50 rpm, with acceptance above 80% at 30 min after reconstitution in purified water. Particle-size stability is checked by sieve analysis per Ph. Eur. 2.9.12; a shift in the fraction below 250 µm of more than 5% after storage indicates cohesive granule formation and requires reformulation of the anti-caking system. Humidity ingress above 2.0% w/w moisture in the sachet is a rejection criterion.

Sterile-Filterable Solutions at pH 6.5–7.5 and the 0.22 µm Membrane Limit

Ionization of aceclofenac in aqueous media is governed by its carboxylic acid group with pKa in the range 4.5–4.7. Below this range the molecule remains largely non-ionized and its water solubility is below 0.1 mg/mL. Solubilization for injectable solutions therefore requires pH elevation to 6.5–7.5, where the ionized fraction exceeds 99% and solubility rises sharply. pH adjustment is performed with meglumine, L-lysine, or sodium hydroxide; meglumine is often selected because it provides a bulky counterion that reduces crystal growth after pH drift. The target concentration for a 150 mg dose is commonly formulated at 25–75 mg/mL to allow an injection volume of 2–6 mL. Co-solvents such as propylene glycol at 10–40% v/v, PEG 300, or ethanol are used to maintain solubility when the formulation is diluted with normal saline. This is a critical limitation: dilution with 0.9% NaCl below a 1:10 volume ratio can reduce co-solvent concentration below the solubility threshold and cause precipitation of aceclofenac crystals. Dilution compatibility must be confirmed by dynamic light scattering or visual inspection per USP <790>. Sterile filtration through a 0.22 µm PVDF or PES membrane is the standard method for sterilizing the bulk solution because terminal steam sterilization at 121°C accelerates ester hydrolysis and produces sub-visible particles above the limits of Ph. Eur. 2.9.19 or USP <788>. Aseptic processing follows Ph. Eur. 5.1.1 and Ph. Eur. 5.1.2, with filter integrity testing performed before and after filling by bubble point or diffusive flow. Nitrogen blanketing during solution preparation reduces oxidative degradation of the aromatic amine. Sodium metabisulfite at 0.1% w/v may be added as an antioxidant when the formulation pH is above 7.0, but sulfite sensitivity in some patient populations must be declared on the label. Tonicity is adjusted with sodium chloride or mannitol to 270–328 mOsm/kg per USP <785>. The most frequent production failure in aseptic filling of aceclofenac solutions is filter clogging before the full batch volume is passed; this occurs when the bulk solution is not pre-filtered through a 0.45 µm clarification membrane and when pH drift causes local supersaturation near the filter surface.

Lyophilized Cake Collapse Is Prevented by Maintaining Shelf Temperature Below the Collapse Point

When aqueous injectable solutions of aceclofenac fail short-term stability due to hydrolytic degradation, lyophilized powder for reconstitution is manufactured for intravenous or intramuscular administration after dilution. The formulation includes bulking agents such as mannitol, glycine, trehalose, or lactose at 2–5% w/v. The fill solution is prepared at pH 6.5–7.5 using the same salt-forming agent as the liquid injection. The solution is filled into depyrogenated glass vials under Grade A conditions and loaded into a freeze dryer with shelf thermal uniformity of ±1°C at -40°C. Primary drying is performed below the collapse temperature of the formulation; published data for aceclofenac-specific collapse temperatures is limited, and freeze-drying microscopy plus modulated differential scanning calorimetry is mandatory during cycle development. Mannitol-containing formulations may show a eutectic melting event near -2°C, requiring primary drying shelf temperatures between -20°C and 5°C depending on fill depth and chamber pressure. Chamber pressure is controlled between 0.1–0.2 mbar during primary drying; a pressure rise test is used to confirm endpoint. Secondary drying is performed at 25–40°C for 4–12 h to achieve residual moisture below 3.0% w/w by Karl Fischer titration per Ph. Eur. 2.5.12. The lyophilized cake must be intact, uniform in color, and free of collapse or meltback. Reconstitution with water for injection requires less than 2 min to produce a clear solution without visible particles. Stopper selection is based on moisture vapor transmission; fluoropolymer-coated halobutyl stoppers are used to limit moisture ingress over 24 months. Headspace oxygen is reduced to below 1.0% v/v by nitrogen flushing before stoppering. The most frequent production failure is incomplete sublimation in the center vials of a full load, caused by insufficient shelf temperature ramp rate; this is corrected by reducing fill volume from 5 mL to 3 mL or increasing primary drying time by 20–30%.